Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Minimal Change Disease Clear all
Not listed Not applicable Interventional
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Balance Training, Breathing and Stretching Exercises
Other
Lead sponsor
Texas Woman's University
Other
Eligibility
60 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Houston, Texas • Sugar Land, Texas • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced May 21, 2026, 10:06 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Hematologic Neoplasms
Interventions
BPX-501, Rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2033
U.S. locations
5
States / cities
Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced May 21, 2026, 10:06 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
GDX012 Suspension for IV Infusion
Biological
Lead sponsor
GammaDelta Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced May 21, 2026, 10:06 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions
WAL0921, Placebo
Drug
Lead sponsor
Walden Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced May 21, 2026, 10:06 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure, Unexplained Proteinuria
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
2,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced May 21, 2026, 10:06 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions
trascutaneous auricular vagus nerve stimulation, Sham device
Device
Lead sponsor
Northwell Health
Other
Eligibility
3 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New Hyde Park, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 10:06 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 10:06 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Interventions
D-Galactose
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2014 · Synced May 21, 2026, 10:06 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
23 Years to 79 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced May 21, 2026, 10:06 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
DaraVRD/DaraVCD
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced May 21, 2026, 10:06 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Idiopathic Nephrotic Syndrome
Interventions
Standard of Care, UrApp
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced May 21, 2026, 10:06 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Kidney Disease, Glomerular Disease, Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Collapsing Glomerulopathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced May 21, 2026, 10:06 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Treatment Resistant Nephrotic Syndrome
Interventions
ACTHAR gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced May 21, 2026, 10:06 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic
Interventions
CART 19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced May 21, 2026, 10:06 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
ADX-629
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
11
States / cities
Northridge, California • Aurora, Colorado • Lauderdale Lakes, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced May 21, 2026, 10:06 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions
Communication
Other
Lead sponsor
University of Michigan
Other
Eligibility
1 Year to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 10:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis
Biological · Procedure · Other
Lead sponsor
Sumithira Vasu
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced May 21, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Secretin
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 15 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced May 21, 2026, 10:06 PM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Insomnia Disorder, Cognitive Functioning
Interventions
CBTi: Stimulus Control Core, CBTi: Sleep Restriction Core, CBTi: Sleep Compression Core
Behavioral
Lead sponsor
Idaho State University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pocatello, Idaho
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Pantoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
51
States / cities
Alabaster, Alabama • Huntsville, Alabama • Mesa, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced May 21, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced May 21, 2026, 10:06 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Adult Acute Lymphoblastic Leukemia, Interleukin-3 Receptor Subunit Alpha Positive, Minimal Residual Disease, Refractory Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis, Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes, Fludarabine Phosphate
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced May 21, 2026, 10:06 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
Interventions
FSGS/TR-MCD, Diabetic Nephropathy (DN)
Other
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Mesa, Arizona • Glendale, California • Victorville, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced May 21, 2026, 10:06 PM EDT